ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
A nomogram predicting the OS and CSS of ≥ T1b renal cell carcinoma patients after surgery.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to develop and validate a nomogram for predicting the overall survival (OS) and cancer-specific survival (CSS) of renal cell carcinoma (RCC) patients after surgery.
methodsFrom 2010 to 2021, clinical data of ≥ T1b RCC patients underwent surgical intervention were retrieved from Surveillance, Epidemiology, and End Results (SEER) database. All enrolled patients were randomly allocated to a training set and a validation set. Variables were screened using Least absolute shrinkage and selection operator (LASSO) regression and Cox regression was employed to develop nomograms. The accuracy of these nomograms was evaluated using the concordance index (C-index), receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).
resultsA total of 4,429 patients were included in this study, with 3,101 and 1,328 patients in the training and validation set, respectively. Multivariate analysis indicated that Grade, Tumor size, Tumor (T), Node (N), Metastasis (M) stage, and Radiation were common independent prognostic factors for OS and CSS in RCC patients. The C-index and ROC curves demonstrated that the two nomograms for OS and CSS had favorable discrimination and calibration ability. DCA indicated that the nomograms achieved more clinical net benefits than the American Joint Committee on Cancer (AJCC) staging system. Additionally, patients were divided into high-risk and low-risk groups based on the nomogram scores. The Kaplan-Meier curves demonstrated significant differences in OS and CSS between the two groups.
conclusionWe developed and validated two effective prognostic nomograms designed to predict 1-, 3-, and 5-year OS and CSS rates for ≥ T1b RCC patients, which can serve as an important supplement to the present predictive models.
Indexed as
Identifiers
42184075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.